prod:prod_dcx-login
Xpert® Xpress GBS
Dual target for S. agalactiae (DNA) Serotypes I-X and non-beta hemolytic in 30–42 minutes
Sign in or create a MyCepheid account to add items to cart
Test pack size(s)
10 Tests
XPRSGBS-CE-10
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Collection devices
Collection Device (Pack of 50)
900-0370
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Total
{{currency}}
0
Error adding items to cart. If this error persists, please contact Digital Support
The Need
Group B Streptococcus (GBS) remains a leading cause of early-onset neonatal sepsis. Rates of maternal colonisation have not changed, but universal antenatal screening at 35–37 weeks along with the use of intrapartum antibiotic prophylaxis (IAP) has resulted in a decrease of early-onset disease.1
Challenges remain, including:
Challenges remain, including:
- Risk of change of GBS colonization status following screening at 35–37 weeks of gestation2,3
- Some women with unknown GBS status presenting at Labor & Delivery units4,5
- Risk-based IAP exposes 65–85% of GBS-negative women to antibiotics6
- 69% sensitivity of antenatal culture for GBS detection when compared to intrapartum culture7
1 Wicker E, et al. Group B streptococci: declining incidence in infants in Germany. Pediatr Infect Dis J. 2019 May;38(5):516–9.
2 Helmig R, et al. Diagnostic accuracy of polymerase chain reaction for intrapartum detection of Group B Streptococcus colonization. Acta Obstet Gynecol Scand. 2017 Sep;96(9):1070-1074.
3 Melin P. Neonatal group B streptococcal disease: from pathogenesis to preventive strategies. Clin Microbiol Infect. 2011 Sep;17(9):1294-303.
4 Di Renzo et al. Intrapartum GBS screening and antibiotic prophylaxis: a European consensus conference. J Maternal Fetal Neonatal Med. 2014:1-17. Available at: https://pubmed. ncbi.nlm.nih.gov/25162923
5 ASM, March 2020, Guidelines for the Detection and Identification of Group B Streptococcus - Revised Guidelines from CDC, 2020
6 Saari A, et al. Antibiotic exposure in infancy and risk of being overweight in the first 24 months of life. Pediatrics. 2015 Apr;135(4):617–626.
7 Young BC, et al. Evaluation of a rapid, real-time intrapartum group B streptococcus assay. Am J Obstet Gynecol. 2011 Oct;205(4):372.e1-6.
2 Helmig R, et al. Diagnostic accuracy of polymerase chain reaction for intrapartum detection of Group B Streptococcus colonization. Acta Obstet Gynecol Scand. 2017 Sep;96(9):1070-1074.
3 Melin P. Neonatal group B streptococcal disease: from pathogenesis to preventive strategies. Clin Microbiol Infect. 2011 Sep;17(9):1294-303.
4 Di Renzo et al. Intrapartum GBS screening and antibiotic prophylaxis: a European consensus conference. J Maternal Fetal Neonatal Med. 2014:1-17. Available at: https://pubmed. ncbi.nlm.nih.gov/25162923
5 ASM, March 2020, Guidelines for the Detection and Identification of Group B Streptococcus - Revised Guidelines from CDC, 2020
6 Saari A, et al. Antibiotic exposure in infancy and risk of being overweight in the first 24 months of life. Pediatrics. 2015 Apr;135(4):617–626.
7 Young BC, et al. Evaluation of a rapid, real-time intrapartum group B streptococcus assay. Am J Obstet Gynecol. 2011 Oct;205(4):372.e1-6.
The Solution
- Cepheid's Xpert® Xpress GBS test is the only in vitro diagnostic test to fully meet the GBS European consensus criteria for rapid intrapartum GBS testing.4 The Xpert Xpress GBS test delivers rapid results with 93.5% sensitivity* and 95.5% specificity.*
- Dual targets in highly conserved regions for an extended GBS strain coverage
- Test designed with Early Assay Termination (EAT) to provide positive results in approximately 30 mins
- Easy-to-use testing with 1 min hands-on time
- Intrapartum rectal/vaginal swabs can be tested by trained lab, or labor and delivery staff
- Sample Adequacy Control integration to ensure correct sample incorporation into the cartridge
- Random access enables any test in the menu to be run at any time, without the need to batch
* Sensitivity and specificity results for intrapartum vaginal/rectal.
4 Di Renzo et al. Intrapartum GBS screening and antibiotic prophylaxis: a European consensus conference. J Maternal Fetal Neonatal Med. 2014:1-17. Available at: https://pubmed. ncbi.nlm.nih.gov/25162923
4 Di Renzo et al. Intrapartum GBS screening and antibiotic prophylaxis: a European consensus conference. J Maternal Fetal Neonatal Med. 2014:1-17. Available at: https://pubmed. ncbi.nlm.nih.gov/25162923
The Impact
The Xpert Xpress GBS test can easily be run in near-patient settings by trained non-laboratory personnel. Now clinicians are able to identify GBS colonisation status when it matters most.
Impact on Patient Pathway
- Identify GBS colonisation status at the time of labor
- Fast and easy to interpret results, enables timely appropriate treatment preventing early onset of GBS disease in newborns
- Reduce unnecessary use of intrapartum antibiotic prophylaxis (IAP)
– Reduce overall hospital cost8
– Reduce length of stay9
– Streamline patient management
– Less impact on newborn intestinal flora10
Impact on Patient Pathway
8 Picchiassi E, et al. Intrapartum test for detection of Group B Streptococcus colonization during labor. J Matern Fetal Neonatal Med. 2018 Dec;31(24):3293-330.
9 Björklund V, et al. Replacing risk-based early-onset-disease prevention with intrapartum group B streptococcus PCR testing. J Matern Fetal Neonatal Med. 2017 Feb;30(3):368-373
10 Zimmermann P, et al. Effect of intrapartum antibiotics on the intestinal microbiota of infants: a systematic review. Arch Dis Child Fetal Neonatal Ed. 2020 Mar;105(2):201–8
9 Björklund V, et al. Replacing risk-based early-onset-disease prevention with intrapartum group B streptococcus PCR testing. J Matern Fetal Neonatal Med. 2017 Feb;30(3):368-373
10 Zimmermann P, et al. Effect of intrapartum antibiotics on the intestinal microbiota of infants: a systematic review. Arch Dis Child Fetal Neonatal Ed. 2020 Mar;105(2):201–8
